Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Inhibrx Biosciences, Inc. (INBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: INBX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 23.14% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 220.18M USD | Price to earnings Ratio 0.13 | 1Y Target Price 12 |
Price to earnings Ratio 0.13 | 1Y Target Price 12 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 10.80 - 17.79 | Updated Date 06/22/2025 |
52 Weeks Range 10.80 - 17.79 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 119.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 861485.5% | Operating Margin (TTM) -116231.5% |
Management Effectiveness
Return on Assets (TTM) -107.28% | Return on Equity (TTM) 41.18% |
Valuation
Trailing PE 0.13 | Forward PE - | Enterprise Value 110188499 | Price to Sales(TTM) 1100.89 |
Enterprise Value 110188499 | Price to Sales(TTM) 1100.89 | ||
Enterprise Value to Revenue 550.94 | Enterprise Value to EBITDA 0.06 | Shares Outstanding 14475900 | Shares Floating 7712906 |
Shares Outstanding 14475900 | Shares Floating 7712906 | ||
Percent Insiders 27.19 | Percent Institutions 68.12 |
Upturn AI SWOT
Inhibrx Biosciences, Inc.
Company Overview
History and Background
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel biologic therapeutic candidates. Founded in 2010, it leverages its proprietary discovery platform to create targeted therapies for cancer and other diseases. The company has advanced multiple candidates into clinical development, reflecting a focus on innovation and addressing unmet medical needs.
Core Business Areas
- Oncology: Development of antibody-based therapies for various cancer types. Focuses on novel targets and mechanisms of action to improve patient outcomes.
- Inflammation and Autoimmune Diseases: Developing therapies targeting inflammatory pathways and autoimmune disorders, aiming to provide targeted treatments with improved efficacy and safety profiles.
Leadership and Structure
The leadership team includes Mark Lappe (CEO). The company has a typical biopharmaceutical organizational structure with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- INBRX-101: A human recombinant protein designed to enhance the Fas-mediated apoptosis pathway for cancer treatment. Currently in clinical trials. Competitors include companies developing similar targeted therapies, such as Amgen and Genentech (Roche).
- INBRX-109: A tetravalent bispecific antibody targeting multiple proteins implicated in various diseases. Currently in early clinical development. Competitors include Regeneron and AbbVie, which are developing bispecific antibodies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. Increasing demand for novel therapies, driven by an aging population and rising prevalence of chronic diseases, is fueling growth.
Positioning
Inhibrx Biosciences, Inc. is positioned as an innovator in the antibody-based therapeutics space. Its competitive advantages include its proprietary discovery platform and pipeline of novel drug candidates.
Total Addressable Market (TAM)
The total addressable market for oncology and inflammatory diseases is estimated to be billions of dollars. Inhibrx is targeting specific segments within these markets with its novel therapies, aiming to capture a portion of the overall market.
Upturn SWOT Analysis
Strengths
- Proprietary discovery platform
- Novel drug candidates in clinical development
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on clinical trial success
- Relatively small commercial infrastructure
- Pipeline risk associated with drug development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through internal discovery and acquisitions
- Advancement of clinical candidates to commercialization
- Potential for breakthrough therapies addressing unmet medical needs
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Changes in healthcare policies and reimbursement
Competitors and Market Share
Key Competitors
- AMGN
- RHHBY
- ABBV
- MRK
Competitive Landscape
Inhibrx faces significant competition from established pharmaceutical giants with greater resources and broader pipelines. Its success depends on demonstrating the superior efficacy and safety of its novel therapies.
Major Acquisitions
Sanofi
- Year: 2024
- Acquisition Price (USD millions): 1700
- Strategic Rationale: Sanofi is acquiring Inhibrx to gain access to its pipeline of novel biologics, particularly INBRX-101, and its protein engineering technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by advancement of its pipeline and strategic partnerships.
Future Projections: Future growth depends on the success of its clinical programs and potential commercialization of its drug candidates. Projections unavailable.
Recent Initiatives: Recent initiatives include advancing clinical trials for its lead candidates and securing funding for ongoing research and development.
Summary
Inhibrx Biosciences is a clinical-stage biopharmaceutical company with a promising pipeline of novel therapies, particularly in oncology. The company's acquisition by Sanofi validates its technology and pipeline. The key strength lies in its innovation, although commercial scaling will depend on Sanofi's capabilities. Threats include clinical trial risks and competition, but the acquisition mitigated those risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available sources. Clinical trial outcomes are uncertain and can impact company valuation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inhibrx Biosciences, Inc.
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2024-05-29 | Founder, CEO & Chairman Mr. Mark Paul Lappe | ||
Sector Healthcare | Industry Biotechnology | Full time employees 156 | Website https://inhibrx.com |
Full time employees 156 | Website https://inhibrx.com | ||
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.